Compare Johnson & Johnson (JNJ) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs SkyWest Inc — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while SkyWest Inc trades at $96.57 (market cap $3.75B). The key difference: Johnson & Johnson is far larger — about 164.8× SkyWest Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and SkyWest Inc for 8 Days on average.
| JNJ | SKYW | |
|---|---|---|
Market Cap | $618.09B | $3.75B |
Volume | 6,050,983 | 196,324 |
Sector | Health | Industrials |
52-Week High | $278.43 | $115.94 |
52-Week Low | $186.00 | $78.40 |
Typical Hold Time | 129 Days | 8 Days |
Enterprise Value | $646.37B | $5.54B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
SkyWest (SKYW) trades at $96.64, down 1.1% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics, including a P/E of 9.6 and P/S of 0.94, while maintaining solid profitability with a 9.78% net income margin. Recent earnings have been mixed, with a Q1 2026 beat but a Q2 2026 miss. Positive developments include fleet modernization efforts and expanded flying agreements, though cost pressures remain a concern.
The investment case balances strong analyst support—58.82% recommend Buy with a $112 consensus target—against near-term technical weakness and earnings volatility. Upside potential exists from operational improvements and cash flow growth, but risks include execution on cost management and broader airline industry challenges. The stock presents a value opportunity for patient investors despite current bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
